Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04811339 · ClinicalTrials.gov registry record · Phase 4
Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)
A Phase 4 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT04811339: Completed Phase 4 study, sponsored by University of Cincinnati.
NCT04811339 is a Phase 4 study that has completed, run by University of Cincinnati. The registered enrollment target is 60 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04811339, a Phase 4 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The Center for Disease Control (CDC) and World Health Organization (WHO) have deemed the COVID-19 virus a global pandemic of unprecedented severity in modern times. In 2019, this novel Coronavirus (COVID-19) emerged from the Asian continent and has now caused upwards of 1million deaths and over 6 million infections globally. Currently, the estimated global economic impact is over 5 Trillion dollars. Understanding the host response to pathogens, specifically the cellular and humoral responses, has played an important role in new non-antibiotic therapies. Bismuth subsalicylate (Pepto-Bismol) has a potential role in the clearance and/or recurrence of enteric viral infections.
Primary Outcome
Number of bowel movements recorded over the 3 day study. Baseline (BL) /day1 + Day 2 + Day 3
Interventions
- DRUG Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable
- OTHER Placebo oral tablet without BSS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-10-27 |
| Est. Completion | 2021-08-15 |
| Phase | Phase 4 |
What the finished NCT04811339 record still lists
NCT04811339 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable is the first listed.
NCT04811339 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04811339 about?
NCT04811339 is a clinical study titled "Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)". The Center for Disease Control (CDC) and World Health Organization (WHO) have deemed the COVID-19 virus a global pandemic of unprecedented severity in modern times. In 2019, this novel Coronavirus (COVID-19) emerged from the Asian continent and has now caused upwards of 1million deaths and over 6 mi...
What is the current status of trial NCT04811339?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2020-10-27. Estimated completion is 2021-08-15.
What interventions are being tested in trial NCT04811339?
The interventions under investigation include: Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable (DRUG), Placebo oral tablet without BSS (OTHER).
Who is sponsoring clinical trial NCT04811339?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04811339's enrollment target sits among peer trials
60 1125th of 2000 higher than 799 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI